Study Type
|
Phase
|
Title
|
| Interventional (prospective) |
II/III |
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas |
| Observational (prospective) |
|
Asymptomatic Small Pancreatic Endocrine Neoplasms. (ASPEN) |
| Observational (prospective/retrospective) |
|
Mantenimento o sospensione della terapia con analoghi della Somatostatina (SSA) dopo progressione di malattia in pazienti con tumori neuroendocrini gastropancreatici di grado 1-2 (GEP NET G1-G2) e toracici (carcinoidi tipici e atipici di polmone e timo) ELIOS STUDY |
| Observational (retrospective) |
|
Resezione curativa nelle neoplasie neuroendocrine digestive: tasso di sopravvivenza libero da recidiva e definizione di uno score di recidiva |
| Interventional (prospective) |
III |
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2) |
| Interventional (prospective) |
II |
A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) |
| Interventional (prospective) |
II |
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors (MK-6482-015) |
| Observational (prospective) |
|
Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs (REAL-LU) |
| Observational (prospective/retrospective) |
|
ITANET Registry: Multicenter registry of GEP-NET |
| Observational (prospective) |
|
Quality of life and sexual function in patients with well differentiated neuroendocrine tumors |
| Observational (prospective) |
|
Health‑related quality of life in patients with neuroendocrine neoplasms |
| Observational (retrospective) |
|
Identificazione di predittori molecolari di risposta alla terapia radiorecettoriale in pazienti con GEP-NETs |
| Observational (prospective) |
|
Financial Toxicity and Patient-Reported Outcomes in GEP-NEN During Treatment (FiReNEN) |
